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ABSTRACT 
Hepatitis C virus (HCV) is a bloodborne infection that causes both acute and chronic 
hepatitis that may lead to liver disease, cirrhosis, or liver cancer. Hepatitis C is a national and 
global public health problem. About 71 million people globally are chronically infected with 
hepatitis C and an estimated 3-4 million people are chronically infected with hepatitis C in the 
United States. Annually, about 399,000 people die worldwide from hepatitis C infection and 
approximately 20,000 people die from HCV-related liver disease in the U.S. Most people with 
hepatitis C infection are asymptomatic and about half of people do not know that they are 
infected. Hepatitis C is a reportable disease in Pennsylvania; therefore, the Allegheny County 
Health Department (ACHD) receives reports of hepatitis C for residents of Allegheny County, 
Pennsylvania. Starting in 2015, ACHD conducted enhanced surveillance activities for hepatitis C 
cases which included faxing one-page questionnaires to healthcare providers who had patients 
with at least one HCV positive laboratory test and conducting patient phone interviews to collect 
risk factor and exposure information. Disease surveillance is important to public health because 
it helps identify which populations need interventions to prevent transmission of the disease, 
morbidity, and mortality. The purpose of this study is to describe the trends in hepatitis C cases 
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from 2007 to 2016 and the reported past/present hepatitis C cases from 2015 to 2016 in 
Allegheny County, Pennsylvania. 
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1.0  INTRODUCTION 
Hepatitis C virus (HCV) is a bloodborne infection that causes both acute and chronic 
hepatitis C that may lead to liver disease, liver cancer, or cirrhosis1. Hepatitis C is a public health 
problem. About 71 million people globally are chronically infected with hepatitis C and about 3-
4 million are chronically infected with hepatitis C in the United States1,2. Each year, 
approximately 399,000 people worldwide die from hepatitis C infection.2 Of those infected with 
hepatitis C, 75%-85% will develop chronic infection, 60%-70% will develop chronic liver 
disease, 5%-20% will develop cirrhosis, and 1%-5% will die from chronic infection.1 About 
15%-25% of people infected with HCV spontaneously clear the infection without treatment.1 
The reason for this is still unknown to researchers.1 Development of acute hepatitis C infection is 
less common, and about 20%-30% of newly infected HCV cases develop acute illness symptoms 
such as fatigue, abdominal pain, jaundice, and loss of appetite.1 
Hepatitis C is most commonly transmitted through the use of injection drugs, sharing 
drugs and equipment, and reusing needles or syringes.2 It can also be transmitted from the use of 
unsterilized medical equipment or from transfusions of blood and other blood products.2 
Additionally, HCV can be transmitted sexually or through maternal transmission but is not as 
common.2 Sexual transmission of HCV has been shown to be about 3%.1 According to the 
Centers for Disease Control and Prevention (CDC), approximately 6 out of every 100 infants 
born to an HCV positive mother will become infected.1 Before blood screening began in the U.S. 
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in 1992, HCV was most commonly transmitted through blood transfusions.1 For this reason, the 
CDC recommends HCV testing for all people born between the years 1945 and 1965.1 In 
resource limited countries, HCV is mostly transmitted from the use of unsterilized needles, 
syringes, and medical equipment.2  
Hepatitis C virus is a bloodborne infection, which has many risk factors. People at high 
risk include those who have used injection drugs even just once in their life, recipients of blood 
clotting factors made prior to 1987, recipients of blood transfusions or solid organ transplants 
before July of 1992, patients who have received long-term hemodialysis, people who are infected 
with HIV, people who have received tattoos or body piercings with unclean needles, and children 
who were born to HCV positive mothers.1,3 People who have known exposures to HCV, such as 
healthcare workers with needlesticks from HCV positive blood and recipients of blood products 
or organs from HCV positive donors, are also at risk of contracting HCV.1 Ways to reduce the 
risk of HCV infection include not using injection drugs, using clean needles and equipment if 
injecting drugs, not sharing needles and equipment if injecting drugs, not sharing personal items 
that may have blood on them (i.e. toothbrushes, razors), and refraining from sex or contact of 
blood with people who are HCV positive.1 
Several diagnostic tests can be performed to determine whether a person is HCV positive. 
Tests that can be used are the antibody HCV test (anti-HCV), enzyme immunoassay (EIA), 
enhanced chemiluminescence immunoassay (CIA), and the HCV RNA polymerase chain 
reaction (PCR) test.1 The PCR test is referred to as the confirmatory test because it can detect the 
absence or presence of HCV and the amount of the virus.1 The most common tests that are 
conducted are the anti-HCV test and the confirmatory RNA PCR test.1 The confirmatory test is 
always recommended even if the antibody test has been done because someone can have a 
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positive HCV antibody test but not currently be infected with hepatitis C.1 The RNA test can 
determine whether a person is currently infected with hepatitis C.1 Testing is recommended for 
people born between 1945-1965, anyone who has ever injected drugs, people with chronic liver 
disease or abnormal liver tests, and people infected with HIV or AIDS.1 Testing is also 
recommended for people who received or donated blood products prior to 1992, those who have 
been exposed to blood in their workplace via needlestick or puncture, people who have received 
hemodialysis, and those who were born to HCV positive mothers.1 
Approximately 20,000 people die each year from HCV-related liver disease.4,5 There is a 
cure for hepatitis C with several treatment options available.1 Advancements in hepatitis C 
treatment have been made, particularly within the past five years. In fact, the U.S. Food and 
Drug Administration (FDA) approved two new drugs this year for treatment of hepatitis C.6 
Drugs for hepatitis C treatment have vastly improved with regard to the number of side effects 
and the length of treatment. Newer treatments have shorter duration from about 8 to 12 weeks, 
work for a variety of HCV genotypes, and only need to be taken once a day.5 Despite the great 
successes in hepatitis C treatment, a small percentage (16%) of patients infected with hepatitis C 
receive treatment.7 A significant barrier to hepatitis C treatment is access and the cost of 
treatment.8  
HCV has been a nationally notifiable disease since 2003 and is also a reportable disease 
in Allegheny County, PA.1 Therefore, it is required by law that healthcare providers, hospitals, 
and laboratories report HCV cases for residents of Allegheny County, PA to the Allegheny 
County Health Department (ACHD). Prior to 2015, ACHD did not have the staff to conduct 
thorough HCV surveillance. However, starting in 2015, ACHD staff conducted enhanced 
surveillance for all HCV positive cases. These activities included faxing one-page questionnaires 
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to healthcare providers for patients with a positive HCV laboratory test and conducting phone 
interviews to collect more patient information. An interview script and guide were developed by 
ACHD staff using a template from the CDC to obtain patient risk factor/exposure information. 
Routine follow-up calls are normally conducted for reportable diseases in Allegheny County, 
PA. Hepatitis C cases were classified in Pennsylvania’s Electronic Disease Reporting system, 
PA-NEDSS, using the current CDC case definition. In 2016, ACHD staff conducted similar 
surveillance activities but only for people with positive HCV laboratory tests between the ages of 
18-34 and greater than 75 years old. The 18-34 year old age group was chosen because they were 
suspected to be newly infected hepatitis C cases. The purpose of this study is to describe the 
reported past and present hepatitis C cases in Allegheny County, PA from 2007-2016.  
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2.0  METHODS 
All information was collected and stored on an electronic database maintained by ACHD. 
HCV case classification was determined by using the case definition for that year that was 
created by the CDC. Prior to 2015, ACHD did not have the staff to conduct enhanced 
surveillance activities. The hepatitis C data collected from 2007-2016 in Allegheny County, PA 
were used to show trends in the data from this ten-year period. More rigorous hepatitis C 
surveillance was conducted in 2015 and 2016 for the county. The 2015 HCV case definition 
classified chronic hepatitis C cases as past or present hepatitis C cases while the 2016 case 
definition classified them as chronic cases. Figure 1 shows the HCV class classification 
algorithm for the new 2016 case definition. All HCV cases were classified in the state electronic 
disease surveillance system PA-NEDSS.  
Since HCV is a reportable condition, patient and provider contact information was 
obtained and accessed from PA-NEDSS. A one-page questionnaire was faxed to healthcare 
providers who had patients with at least one HCV positive laboratory test to collect information 
on symptoms, other laboratory results, and risk factors. The questionnaire was faxed to 
healthcare providers a second time if they did not return it to ACHD. To find additional risk 
factor/exposure information for HCV positive patients, ACHD staff created an interview guide 
based off of a template provided by the CDC and an introductory script to conduct phone 
interviews. ACHD staff trained two interviewers and a group of graduate students before they 
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started conducting the phone interviews. The graduate students were used due to the large 
number of HCV cases that needed to be contacted for the follow-up calls. In 2015, all HCV cases 
were investigated but this was unsustainable due to the large amount of cases. Consequently, in 
2016, only the HCV cases between the ages of 18-34 and greater than 75 years old were 
investigated. Data were analyzed using Microsoft Excel for descriptive statistics.  
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3.0  RESULTS 
Between 2007 and 2016, there were 11,475 reported probable and confirmed hepatitis C 
cases in Allegheny County, PA. Out of 11,475 cases, 9745 (85%) were classified as confirmed 
and 1730 (15%) were probable. The number of reported probable and confirmed hepatitis C 
cases increased throughout this ten-year period from 643 cases in 2007 and 606 in 2008 to 2123 
in 2015, and 2824 in 2016 (Figure 2).  
As shown in Figure 3, the majority of probable and confirmed hepatitis C cases from 
2007 to 2016 were male (61%). The age distribution was bimodal with peaks between the ages 
of 25-39 (25%) and 50-64 years old (43%). The distribution of race for these cases from 2007 to 
2016 was 41% unknown, 40% White, 16% Black, 2% other, 0.4% Asian, and 0.1% Pacific 
Islander. The majority of probable and confirmed hepatitis C cases from 2007 to 2016 had 
unknown ethnicity (84%).  
The number of pediatric hepatitis C cases for children less than 2 years old and between 
ages 2-9 peaked in 2010 with 7 cases and 2 cases respectively and in 2016 with 6 cases for each 
age group (Figure 4). The number of hepatitis C cases in women of childbearing age (ages 15-
44) increased from 2007 to 2016 where the number of cases in 2016 is almost four times higher 
than the number of cases in 2012 (Figure 5). 
As shown in Figure 6, acute hepatitis C cases peaked in 2015 with 23 cases. There were 
11 acute cases in 20116 which is almost half as many cases in 2015. This may be due to the more 
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aggressive surveillance that ACHD conducted in 2015. ACHD did no follow-up investigation for 
acute cases in years prior to 2015, which explains the minimal number of cases for those years.   
In 2015, there were 2123 reported probable and confirmed hepatitis C cases in Allegheny 
County, PA. Out of 2123 cases, 2012 (95%) were classified as confirmed cases and 111 (5%) 
were probable. The majority of cases were male (61%). The age distribution was bimodal with 
peaks between the ages 20-39 (35%) and 50-69 years old (49%). Out of the 2123 cases, 46% 
were White, 34% had unknown race, 17% were Black, 2% had a race of other, 0.3% were Asian, 
and 0.1% were Pacific Islander. The most common risk factor for interviewed cases was needle 
usage for injection drugs.  
There were 25 acute hepatitis C cases in 2015 and the majority were White (68%) males 
(64%) with a peak between ages 30-39 years old (40%). The age of acute cases is older than 
previously thought. More investigation is needed to explain the peak of acute cases in this 30-39 
year old age group. 
In 2016, there were 2824 reported probable and confirmed hepatitis C cases in Allegheny 
County, PA. Out of 2824 cases, 1628 (58%) were classified as confirmed and 1196 (42%) were 
probable. The majority of cases were male (60%). Case numbers peaked between the ages 20-39 
(34%) and 50-69 years old (50%). Out of the 2824 cases, 47% had unknown race, 34% were 
White, 15% were Black, 5% had a race of “other,” 0.3% were Asian, and 0.1% were Pacific 
Islander. A total of 832 hepatitis C cases between the ages 18-34 years were investigated in 
2016. Out of these cases, 105 (13%) were non-cases, 126 (15%) were incarcerated, 348 (42%) 
had invalid or missing phone numbers, 148 (18%) were left voicemails and did not respond, 86 
(10%) were interviewed, 17 (2%) refused to be interviewed, and 2 (0.2%) were deceased. The 
interview response rate was low at about 10%. Shown in Figure 7, the most common risk factors 
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for the 86 probable and confirmed hepatitis C cases between the ages of 18-34 years old that 
were interviewed were needle usage for injection drugs (74%), tattoos (70%), dental work or oral 
surgery (66%), contact of a hepatitis C case (43%), surgery (42%), employed in field involving 
contact with human blood (12%), received blood or blood products/transfusions (7%), puncture 
with needle or other object contaminated with blood (6%), and acupuncture (5%). Out of the 86 
interviewed cases, only 8 (9%) reported receiving medical treatment and 14 (16%) reported 
receiving medical care specifically for hepatitis C infection. A total of 53 hepatitis C cases aged 
75 years or older were investigated in 2016. Out of these cases, 14 (26%) were non-cases, 15 
(28%) had invalid or missing numbers, 7 (13%) were left voicemails and did not respond, 11 
(21%) were interviewed, 2 (4%) refused to be interviewed, and 4 (8%) were deceased. The 
interview response rate was better for this age group than those aged 18-34 years old at about 
28%. The fax return rate from providers was about 68% while the fax return rate for second 
attempts was lower at about 45%.  
There were less acute hepatitis C cases in 2016 than in 2015, which may be due to the 
more aggressive surveillance that was conducted in 2015. There were 11 acute cases in 2016 and 
the majority of them were male (55%) and between the ages 20-29 years old (55%). The age 
group for these cases has shifted to a younger population than the acute cases in 2015, which 
may be due to not investigating cases for people over the age of 34 years old. The most common 
races were White (45%) and unknown (45%). 
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4.0  DISCUSSION 
Hepatitis C cases in Allegheny County, PA have increased from 2007-2016. This finding 
is consistent with national hepatitis C data.1 Another finding that is consistent with national data 
is that injection drug use was the most common risk factor for hepatitis C cases in both 2015 and 
2016. These findings are not surprising due to the opioid epidemic that is affecting the U.S. and 
Allegheny County in particular. In fact, the CDC reported that hepatitis C related deaths in the 
U.S. reached an all-time high in 2014 surpassing deaths from any other infectious disease.9 In 
2016, Allegheny County had 422 opioid overdose deaths, which were the most overdose deaths 
the county has ever reported.10 The peak in hepatitis C cases for ages 25-39 years old in 
Allegheny County is also the same age group with a significant increase in overdose deaths in 
the county.10 This warrants attention because as the opioid epidemic continues to grow, the 
number of hepatitis C cases will likely continue to increase. Another study finding that is 
consistent with national data is the peak in hepatitis C cases from ages 50-64 years old, or the 
baby boomer population.7 The large number of cases in this age group could be due to the HCV 
screening recommendation by the CDC for this population. Screening is recommended for 
people born between 1945-1965 because they are five times more likely to be infected with 
hepatitis C than any other adult age group.1 This may be due to blood not being screened for 
HCV before 1992.1 A study finding that is inconsistent with national data is that White 
individuals are the most common race for hepatitis C cases in Allegheny County. National data 
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show that chronic hepatitis C infection and hepatitis C-related deaths are most prevalent among 
African Americans.7 This difference in race could be attributed to the large majority of Whites in 
Allegheny County (80.5%) compared to the small percentage of African Americans (13.4%).11  
Hepatitis C surveillance activities need to be improved in Allegheny County to ensure 
collection of accurate data. A large portion of hepatitis C cases in 2016 had unknown race and it 
was the second most common response for race in 2015. Ethnicity was often missing as well. 
These data could be collected more accurately if the healthcare personnel who tested the 
individuals for HCV completed them. Due to the small number of cases who were interviewed, it 
is imperative that healthcare personnel complete as much information on the questionnaire as 
possible about demographic, symptoms, previous laboratory tests, and risk factor information to 
ensure accurate data collection. Consequently, this would create less work for the investigation 
of cases by ACHD staff, which does not have the resources to investigate all hepatitis C cases in 
the county. However, this may not be of interest to the healthcare personnel because they often 
are too busy to complete the information on the questionnaire. Another part of the surveillance 
process at ACHD that needs to be improved is contacting the hepatitis C cases for follow-up 
interviews. Phone interviews proved to be unsuccessful with an interview response rate of only 
10%. Surprisingly, the cases aged 75 years or older had a higher interview response rate than 
cases aged 18-34 years old. People in the younger generation are considered to be frequent 
mobile phone users; therefore, it would be expected that more cases from this age group would 
participate in phone interviews than the cases in the older age group. However, it was not 
determined whether the phone numbers provided were mobile phones or landlines, which could 
make a difference in the phone interview response rate. Other forms of communication could be 
used for the follow-up interviews, such as sending text messages, emails, or online surveys to 
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complete. Since phone calls are not successful for the younger population, using updated 
technology may help to improve the interview response rate. Another improvement that could be 
made to the ACHD surveillance process is making it completely electronic. Eliminating faxes 
would save the ACHD staff time that could be used for conducting follow-up interviews. 
Surveillance is an important process with the goal of describing the burden of disease for 
infectious diseases so interventions can be made to stop the transmission of the disease. 
Attention is warranted to prevent HCV transmission in Allegheny County, especially as the 
opioid epidemic continues to grow. Therefore, concerted effort needs to be given to provide 
accurate and thorough surveillance of hepatitis C cases in Allegheny County. Data collected 
from surveillance can be used to develop and implement interventions to decrease HCV 
transmission and ultimately reduce morbidity and mortality in Allegheny County, PA. 
4.1 LIMITATIONS 
The results of this study are limited to the work and resources that the ACHD allocates 
toward the HCV surveillance process as well as the number of laboratory reports that were sent 
to ACHD. Therefore, the increase in hepatitis C cases could have been influenced by the 
enhanced surveillance activities that the ACHD conducted, particularly in the year 2015 where 
all cases were investigated as opposed to in 2016 where only certain age groups were 
investigated. Additionally, the risk factor data for 2015 and 2016 need to be interpreted with 
caution because multiple risk factors were reported for each person. Due to the small sample size 
of hepatitis C cases that were interviewed in 2016, the results cannot be generalizable to the 
population of Allegheny County, PA. 
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4.2 CONCLUSION 
Hepatitis C cases in Allegheny County, PA have increased within the past decade. The 
majority of these cases in Allegheny County were males aged 25-39 and 50-64 years old and the 
most common risk factor was injection drug use. Interventions need to be developed for these 
populations to decrease the number of hepatitis C cases and prevent transmission of HCV in 
Allegheny County. Particular attention is warranted to injection drug users due to the opioid 
epidemic that has been occurring throughout the U.S. and significantly impacting Allegheny 
County. Improvements need to be made for HCV testing and linkage to care to decrease the 
number of hepatitis C cases and deaths. However, many upstream factors influence these issues 
making interventions harder to develop and implement. Enhanced HCV surveillance conducted 
by ACHD can aid this process but more resources are needed for it to be sustainable.  
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Figure 1- HCV 2016 case classification algorithm 
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*The case definition changed, which may be the reason for the increase in probable cases and decrease in 
confirmed cases 
 
Figure 2- Number of reported past/present hepatitis C cases in Allegheny County, PA from 2007 to 2016 by 
year 
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Figure 3- Distribution of reported past/present hepatitis C cases in Allegheny County, PA by age and sex 
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Figure 4- Number of reported past/present pediatric hepatitis C cases by year for ages less than 2 years and 
ages 2 to 9 years in Allegheny County, PA from 2007 to 2016 
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Figure 5- Number of reported past/present hepatitis C cases in women of childbearing age (15-44 years old) 
by year in Allegheny County, PA from 2007 to 2016 
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Figure 6- Number of reported acute hepatitis C cases in Allegheny County, PA from 2007 to 2016 
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Figure 7- Risk factor information for the interviewed probable and confirmed hepatitis C cases ages 18-34 
years old in Allegheny County, PA in 2016 
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